Lipomics President a Guest Speaker at FDA’s Genomics and Proteomics Interest Group Meeting
News Oct 25, 2005
Lipomics Technologies, Inc. has announced that Steve Watkins, Ph.D., Lipomics founder, president, and chief scientific officer, was a guest speaker at the recent Genomics and Proteomics Interest Group meeting at the Food and Drug Administration (FDA).
Watkins’ presentation addressed metabolomics, focusing on small molecule metabolites that are proximal effectors of health and disease and hold considerable promise in many aspects of drug development and personalized medicine.
“The FDA is clearly thinking to the future by devoting a session of a group generally focused on genomics to the topic of metabolomics,” said Tom Anderson, Ph.D., Lipomics’ CEO.
“The FDA is looking ahead to applications of metabolomics in the drug development process and we are pleased that Steve was asked to provide the overview to this group.”
Chaired by Dr. Norris Alderson, the Associate Commissioner of Science at the FDA, this working group includes leading scientists at each of the seven centers of the FDA.
The Group meets periodically to enable FDA scientific leaders to stay current with the rapidly changing landscape of genomics and proteomics.
What effects does climate change have on the genetic diversity of living organisms? An international team of researchers studied the genome of the alpine marmot, an ice-age remnant that now lives in large numbers in the high altitude Alpine meadow. Results were unexpected: the species was found to be the least genetically diverse of any wild mammal studied to date.